Are insiders buying APGE?

This page tracks SEC Form 4 open-market insider purchases for APGE. We surface a cluster when 2 or more distinct insiders buy within 90 days.

What is an insider cluster buy?

A cluster buy is when two or more distinct company insiders make open-market purchases (SEC Form 4, transaction code P) of the same stock within a short window. Multiple insiders buying at once is a stronger conviction signal than a single purchase.

Where does InsiderCluster get insider data?

Directly from SEC EDGAR Form 4 filings. We track open-market purchases (code P); price and sentiment come from Yahoo Finance and StockTwits.

APGE

NasdaqGM

Apogee Therapeutics, Inc.

$134.09

▼ -0.21 (-0.16%)

Price

-0.16% over 1D

Key statistics

Previous close$134.30

Day range134.05 – 134.35

52-week range34.34 – 134.46

Volume1.74M

CurrencyUSD

ExchangeNasdaqGM

Crowd sentiment

88Bullish

Insider activity

SEC EDGAR ↗

Open-mkt buys

$0.00

Open-mkt sells

$19,174,131.66

Net flow

−19.17M

10 open-market trades

Showing 18 recent filings. 8 other (grants, option exercises, gifts, tax withholding) are listed below but excluded from buy/sell flow.

Insider	Type	Shares	Price	Value	Date
Henderson Jane Chief Financial Officer	Gift	15K	$0.00	—	2026-07-24
Dambkowski Carl Chief Medical Officer	Gift	8K	$0.00	—	2026-07-14
HENDERSON MICHAEL THOMAS Director, Chief Executive Officer	Sell (open market)	20K	$133.63	$2,672,600.00	2026-07-08
HENDERSON MICHAEL THOMAS Director, Chief Executive Officer	Gift	75.05K	$0.00	—	2026-07-10
Dambkowski Carl Chief Medical Officer	Option exercise	4.13K	$22.86	$94,297.50	2026-07-01
Dambkowski Carl Chief Medical Officer	Sell (open market)	5.5K	$132.74	$730,070.00	2026-07-01
Dambkowski Carl Chief Medical Officer	Option exercise	4.13K	$0.00	—	2026-07-01
Dambkowski Carl Chief Medical Officer	Sell (open market)	26.4K	$132.60	$3,500,640.00	2026-06-22
HENDERSON MICHAEL THOMAS Director, Chief Executive Officer	Sell (open market)	80K	$132.54	$10,603,200.00	2026-06-22
HENDERSON MICHAEL THOMAS Director, Chief Executive Officer	Sell (open market)	6.77K	$82.21	$556,561.70	2026-06-10
HENDERSON MICHAEL THOMAS Director, Chief Executive Officer	Sell (open market)	7.65K	$82.78	$633,598.12	2026-06-10
HENDERSON MICHAEL THOMAS Director, Chief Executive Officer	Sell (open market)	1.08K	$84.18	$90,914.40	2026-06-10
HENDERSON MICHAEL THOMAS Director, Chief Executive Officer	Sell (open market)	1.58K	$85.19	$134,344.63	2026-06-10
HENDERSON MICHAEL THOMAS Director, Chief Executive Officer	Sell (open market)	2.31K	$86.27	$198,852.35	2026-06-10
HENDERSON MICHAEL THOMAS Director, Chief Executive Officer	Sell (open market)	614	$86.89	$53,350.46	2026-06-10
Fairmount Funds Management LLC Director	Grant / award	7.66K	$0.00	—	2026-06-09
Shah Nimish P Director	Grant / award	7.66K	$0.00	—	2026-06-09
McKenna Mark C. Director	Grant / award	7.66K	$0.00	—	2026-06-09

Source: SEC EDGAR Forms 4/4A (CIK 1974640). Click an insider to open the original filing.

Social sentiment

Bullish

Volume-weighted across live social sources

StockTwitsLIVE

7 bull881 bear

Recent posts

@NezuRIP· StockTwitsJul 25

$APGE 11 aug

@miller1m· StockTwitsJul 24

$APGE currently higher than the buyout price@135.11

@BostonDave· StockTwitsJul 24

$ALT $APGE $FOLD $TECH $TERN

@BuddyBoy6975· StockTwitsJul 24

$ALT $APGE $FOLD $TECH $TERN So, in your Tern chart, short interest increased over a 6 month period by 1.5-2.5 times its SI 6 months earlier. Wow. Then hit Not fairy tale gobbledygook. Legitimate. Market. Analysis. 👏👏👏👏👏👏👏👏👏👏

@TradeSun· StockTwitsJul 23

$ALT $APGE $FOLD $TECH Short interest of $TERN kept growing and were running into Merck s BO- Offer on March 25 😉👇

@BuddyBoy6975· StockTwitsJul 23

$ALT $APGE $FOLD $TECH Trade, interesting thoughts on WHY we see rising short interest and an increase in Bashers ahead of BO news…

@TradeSun· StockTwitsJul 22

$ALT $APGE $FOLD $TECH What I can tell you without any more dd, Dilution is not uncommon before a deal. Basta!

@HansWurst19· StockTwitsJul 22

$ALT $TECH $APGE $FOLD interesting. Have you matched it with the available shares of those companies? Maybe it's just that they diluted too and mire available shares meant more shorting? Or dilution means upcoming buyout?

@BuddyBoy6975· StockTwitsJul 22

$ALT $APGE $FOLD $TECH Trade, that’s a HELLUVA find. Great job man….🙏🙏😎😎

@TradeSun· StockTwitsJul 22

$ALT $APGE $FOLD $TECH For FSDdingsbums… 👇 @Hatrak1

@Pika_Capital· StockTwitsJul 17

$ORKA $APGE $SYRE Holy moly what a run. In less than a year orka and syre jumped +500%, and apge was bought out. +250% And honestly if it was not about my man Oneil Trader (Growth Stock Forum sub on Seeking Alpha) I probably would not have gotten into these names. Give it a try if you want to grow as biotech investor. SA is full of shit as a platform but he does not want to pivot elsewhere for now. I brought in few guys and noone really complained. If you are reading this and did sub because of my recommendation, comment below and share feedback

@Night_Owl_Biotech· StockTwitsJul 15

$CELC is now the latest addition to our list of 23 commercial-stage oncology focused bios with market caps north of $450MM. Congratulations to CELC No one asked but attached is a comparison of CELC's valuation as a multiple of 5 year (FY28 - 32) & 8-year (FY28 - 35) analyst consensus revenue estimates to 4 very recent peer M&A oncology & non-oncology transactions (all nearing commercial-stage like CELC yesterday). The comp is not perfect but does provide a barometer of CELC potential if analyst estimates are credible & if Gedatolisib is worth peer M&A multiples should CELC exit. This is not investment advice. We're merely sharing 1 analysis of many needed to assess potential. We will update CELC's multiples to its peer oncology focused bios shortly. $CRNX $XBI $IBB $APGE